Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsStephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
Estimating the term…
The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
A nucleic acid encoding a dengue virus or chimeric dengue virus comprising
A method of producing a nucleic acid encoding a dengue virus or chimeric dengue virus comprising introducing a mutation into the 3′ untranslated region (3′-UTR) of DENI or DEN3, wherein the mutation is
A tetravelent immunogenic composition comprising nucleic acids encoding each of DEN1, DEN2, DEN3, and DEN4, wherein each nucleic acid has a Δ30 mutation that removes the TL-2 homologous structure and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes one or more nucleotides in the 5′ direction up to and including nucleotide 258 with reverse-direction numbering.
Dependencies are inferred from the claim text.